# Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

> **NCT02687451** · PHASE3 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Post-Operative Pain
- Acute Pain

## Interventions

- **DRUG:** Oxymorphone HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02687451
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-09-15
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Released from PMR
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02687451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02687451, "Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02687451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*